tirzepatide lawsuit fda Weight loss drug lawsuit: Mounjaro maker files suit over compounded products Novo sues Lilly, claiming misleading

There was no history of diabetes or other cardiovascular risk factors

PlexusDx health questionnaires capture this history to flag potential concerns early

Both medications have the same active ingredient, an injectable originally meant for the management of Type-2 diabetics that also happens to be a potent appetite regulator

82 84 , 163 165 Recommendations 24 Regardless of the serum alanine aminotransferase level, the decision to initiate therapy with pegylated interferon and ribavirin should be individualized based on the severity of liver disease by liver biopsy, the potential for serious side effects, the likelihood of response, and the presence of comorbid conditions (Class I, Level B)